Idarubicin For Myeloma

Chemo Secrets From a Breast Cancer Survivor

Breast Cancer Survivors

Get Instant Access

32. Monconduit M, Menard JF, Michaux JL, et al.: VAD or VMBCP in severe multiple myeloma. The Groupe d'Etudes et de Recherche sur le Myelome (GERM). Br J Haematol 80(2):199-204, 1992.

33. Barlogie B, Kyle RA, Anderson KC, et al.: Comparable survival in multiple myeloma (MM) with high dose therapy (HDT) employing MEL 140 mg/m2 + TBI 12 Gy autotransplants versus standard dose therapy with VBMCP and no benefit from interferon (IFN) maintenance: results of intergroup trial S9321. Session type: oral session [abstract]. Blood 102(11):42a. 2004.

34. Attal M, Harousseau JL, Stoppa AM, et al.: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335(2):91-97, 1996.

35. Salmon SE, Haut A, Bonnet JD, et al.: Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol 1(8):453-461, 1983.

36. Boccadoro M, Marmont F, Tribalto M, et al.: Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and pred-nisone even in high-risk patients. J Clin Oncol 9(3): 444-448, 1991.

37. Barlogie B, Smith L, Alexanian R: Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310(21):1353-1356, 1984.

38. Alexanian R, Barlogie B, Tucker S: VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 33(2):86-89, 1990.

39. Samson D, Gaminara E, Newland A, et al.: Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 2(8668):882-885, 1989.

40. Anderson H, Scarffe JH, Ranson M, et al.: VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer 71(2):326-330, 1995.

41. Phillips JK, Sherlaw-Johnson C, Pearce R, et al.: A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma. Leuk Lymphoma 17(5-6):465-472, 1995.

42. Raje N, Powles R, Kulkarni S, et al.: A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. Br J Haematol 97(1):153-160, 1997.

43. Cavo M, Benni M, Ronconi S, et al.: Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study. Haematologica 87(9):934-942, 2002.

44. Barlogie B, Jagannath S, Desikan KR, et al.: Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93(1):55-65, 1999.

45. Gertz MA, Lacy MQ, Inwards DJ, et al.: Factors influencing platelet recovery after blood cell transplantation in multiple myeloma. Bone Marrow Transplant 20(5):375-380, 1997.

46. Prince HM, Imrie K, Sutherland DR, et al.: Peripheral blood progenitor cell collections in multiple myeloma: predictors and management of inadequate collections. Br J Haematol 93(1):142-145, 1996.

47. Tricot G, Jagannath S, Vesole D, et al.: Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 85(2):588-596, 1995.

48. Dimopoulos MA, Pouli A, Zervas K, et al.: Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Ann Oncol 14(7):1039-1044, 2003.

49. Hussein MA, Wood L, Hsi E, et al.: A phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer 95(10):2160-2168, 2002.

50. Fossa A, Muer M, Kasper C, Welt A, Seeber S, Nowrousian MR: Bolus vincristine and epirubicin with cyclophosphamide and dexamethasone (VECD) as induction and salvage treatment in multiple myeloma. Leukemia 12(3):422-426, 1998.

51. Al-Zoubi A, Emmons R, Walsh W, O'Donnell J, Stewart M, Jani CR: The efficacy and cost of bolus VAD (vin-cristine, doxorubicin, and dexamethasone) administered as a rapid intravenous infusion for untreated multiple myeloma—a phase II study [abstract]. Proc Am Soc Clin Oncol 22:614, 2003.

52. Hussein MA, Wildgust M, Fastenau J, Piech CT: Cost effectiveness of DVd vs VAd in newly diagnosed multiple myeloma [abstract]. Proc Am Soc Clin Oncol 23:567, 2004.

53. Cook G, Sharp RA, Tansey P, Franklin IM: A phase I/II trial of Z-Dex (oral idarubicin and dexamethasone), an oral equivalent of VAD, as initial therapy at diagnosis or progression in multiple myeloma. Br J Haematol 93(4):931-934, 1996.

54. Glasmacher A, Haferlach T, Gorschluter M, et al.: Oral idarubicin, dexamethasone and vincristine (VID) in the treatment of multiple myeloma. Leukemia 11(suppl 5):S22-S26, 1997.

55. Kumar A, Loughran T, Alsina M, Durie BG, Djulbegovic B: Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol 4(5):293-304, 2003.

56. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B: Primary dexamethasone treatment of multiple myeloma. Blood 80(4):887-890, 1992.

57. Facon T, Mary JY, Pegourie B, et al.: Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for highdose therapy. Blood 107(4):1292-1298, 2006.

58. Levine RA, McGuire RF: Corticosteroid-induced pancreatitis: a case report demonstrating recurrence with rechallenge. Am J Gastroenterol 83(10):1161-1164, 1988.

59. Kneller A, Raanani P, Hardan I, et al.: Therapy with thalidomide in refractory multiple myeloma patients— the revival of an old drug. Br J Haematol 108(2): 391-393, 2000.

60. Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C: Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 109(1):89-96, 2000.

61. Rajkumar SV, Fonseca R, Dispenzieri A, et al.: Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 75(9):897-901, 2000.

62. Hus M, Dmoszynska A, Soroka-Wojtaszko M, et al.: Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 86(4):404-408, 2001.

63. Tosi P, Ronconi S, Zamagni E, et al.: Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation. Haematologica 86(4):409-413, 2001.

64. Yakoub-Agha I, Attal M, Dumontet C, et al.: Thalidomide in patients with advanced multiple myeloma: a study of 83 patients—report of the Intergroupe Francophone du Myelome (IFM). Hematol J 3(4):185-192, 2002.

65. Barlogie B, Desikan R, Eddlemon P, et al.: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 98(2):492-494, 2001.

66. Dimopoulos MA, Zervas K, Kouvatseas G, et al.: Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 12(7):991-995, 2001.

67. Palumbo A, Giaccone L, Bertola A, et al.: Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 86(4): 399-403, 2001.

68. Rajkumar SV, Hayman S, Gertz MA, et al.: Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20(21):4319-4323, 2002.

69. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21(1): 16-19, 2003.

70. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR: Phase III clinical trial of thalidomide plus dexametha-sone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.

71. Ghobrial IM, Dispenzieri A, Bundy KL, et al.: Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. Bone Marrow Transplant 32(6):587-592, 2003.

72. Dingli D, Rajkumar SV, Nowakowski GS, et al.: Combination therapy with thalidomide and dexam-ethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. Haematologica 90(12): 1650-1654, 2005.

73. Rajkumar SV, Hussein MA, Catalano L, et al.: A multicenter, randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexam-ethasone alone as initial therapy for newly diagnosed multiple myeloma [abstract]. J Clin Oncol 24(suppl 18S):426S, 2006.

74. Tosi P, Zamagni E, Cellini C, et al.: Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol 73(2):98-103, 2004.

75. Barlogie B, Shaughnessy J, Tricot G, et al.: Treatment of multiple myeloma. Blood 103(1):20-32, 2004.

76. Child JA, Morgan GJ, Davies FE, et al.: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348(19):1875-1883, 2003.

77. MacLennan IC, Chapman C, Dunn J, Kelly K: Combined chemotherapy with ABCM versus melpha-lan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults. Lancet 339(8787):200-205, 1992.

78. Moreau P, Facon T, Attal M, et al.: Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 99(3):731-735, 2002.

79. Barlogie B, Jagannath S, Vesole DH, et al.: Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89(3):789-793, 1997.

80. Lenhoff S, Hjorth M, Holmberg E, et al.: Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 95(1):7-11, 2000.

81. Blade J, Sureda A, Ribera J: High-dose therapy autotransplantation vs continued conventional chemotherapy in multiple myeloma patients responding to initial treatment chemotherapy. Results of a prospective randomized trial from the Spanish Cooperative Group [abstract]. Blood 98:815a, 2001.

82. Segeren CM, Sonneveld P, van der HB, et al.: Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 101(6):2144-2151, 2003.

83. Barlogie B, Kyle RA, Anderson KC, et al.: Standard chemotherapy compared with high-dose chemoradio-therapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 24(6):929-936, 2006.

84. Fermand JP, Ravaud P, Chevret S, et al.: High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92(9):3131-3136, 1998.

85. Desikan R, Barlogie B, Sawyer J, et al.: Results of highdose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 95(12):4008-4010, 2000.

86. Facon T, Avet-Loiseau H, Guillerm G, et al.: Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 97(6):1566-1571, 2001.

87. Worel N, Greinix H, Ackermann J, et al.: Deletion of chromosome 13q14 detected by fluorescence in situ hybridization has prognostic impact on survival after high-dose therapy in patients with multiple myeloma. Ann Hematol 80(6):345-348, 2001.

88. Fonseca R, Harrington D, Oken MM, et al.: Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study. Cancer Res 62(3):715-720, 2002.

89. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B: Graft-versus-myeloma effect: proof of principle. Blood 87(3):1196-1198, 1996.

90. Libura J, Hoffmann T, Passweg J, et al.: Graft-versus-myeloma after withdrawal of immunosuppression following allogeneic peripheral stem cell transplantation. Bone Marrow Transplant 24(8):925-927, 1999.

91. Alyea E, Weller E, Schlossman R, et al.: Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-ver-sus-myeloma effect. Bone Marrow Transplant 32(12):1145-1151, 2003.

92. Bjorkstrand BB, Ljungman P, Svensson H, et al.: Allogeneic bone marrow transplantation versus autolo-gous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 88(12):4711-4718, 1996.

93. Laterveer L, Verdonck LF, Peeters T, Borst E, Bloem AC, Lokhorst HM: Graft versus myeloma may overcome the unfavorable effect of deletion of chromosome 13 in multiple myeloma. Blood 101(3):1201-1202, 2003.

94. Badros A, Barlogie B, Siegel E, et al.: Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 20(5):1295-1303, 2002.

95. Maloney DG, Molina AJ, Sahebi F, et al.: Allografting with nonmyeloablative conditioning following cytore-ductive autografts for the treatment of patients with multiple myeloma. Blood 102(9):3447-3454, 2003.

96. Singhal S, Safdar A, Chiang KY, et al.: Non-myeloablative allogeneic transplantation ('microallograft') for refractory myeloma after two preceding autografts: feasibility and efficacy in a patient with active aspergillosis. Bone Marrow Transplant 26(11):1231-1233, 2000.

97. Palumbo A, Triolo S, Argentino C, et al.: Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 94(4):1248-1253, 1999.

98. Reece DE, Bredeson C, Perez WS, et al.: Autologous stem cell transplantation in multiple myeloma patients <60 vs >/=60 years of age. Bone Marrow Transplant 32(12):1135-1143, 2003.

99. Siegel DS, Desikan KR, Mehta J, et al.: Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 93(1):51-54, 1999.

100. Sirohi B, Powles R, Mehta J, et al.: The implication of compromised renal function at presentation in myeloma: similar outcome in patients who receive high-dose therapy: a single-center study of 251 previously untreated patients. Med Oncol 18(1):39-50, 2001.

101. Badros A, Barlogie B, Siegel E, et al.: Results of autolo-gous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 114(4):822-829, 2001.

102. Lee CK, Zangari M, Barlogie B, et al.: Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotrans-plant. Bone Marrow Transplant 33(8):823-828, 2004.

103. Fassas A, Tricot G: Results of high-dose treatment with autologous stem cell support in patients with multiple myeloma. Semin Hematol 38(3):231-242, 2001.

104. Palumbo A, Bringhen S, Bertola A, et al.: Multiple myeloma: comparison of two dose-intensive melpha-lan regimens (100 vs 200 mg/m(2)). Leukemia 18(1): 133-138, 2004.

105. Morris C, Iacobelli S, Brand R, et al.: Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study. J Clin Oncol 22(9):1674-1681, 2004.

106. Palumbo A, Bertola A, Musto P, et al.: Oral melphalan, prednisone, and thalidomide for newly diagnosed myeloma patients [abstract]. Proc Am Soc Clin Oncol 23:567, 2004.

107. Palumbo A, Bringhen S, Caravita T, et al.: Oral melpha-lan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367(9513):825-831, 2006.

108. Facon T, Mary JY, Harousseau JL, et al.: Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. J Clin Oncol 24(suppl 18S):1S, 2006.

109. Agrawal NR, Hussein M, Elson P, Karam M, Reed J, Srkalovic G: Pegylated doxorubicin (DOX), vincristine (V), reduced frequency dexamethasone (d), and thalidomide (T) (DVd-T) in newly diagnosed (nmm) and relapsed refractory (rmm) multiple myeloma patients [abstract]. Blood 102(11):237a, 2004.

110. Lee CK, Barlogie B, Munshi N, et al.: DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. JClin Oncol 21(14):2732-2739, 2003.

111. Zangari M, Siegel E, Barlogie B, et al.: Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 100(4): 1168-1171, 2002.

112. Zangari M, Anaissie E, Barlogie B, et al.: Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98(5):1614-1615, 2001.

113. Richardson PG, Barlogie B, Berenson J, et al.: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348(26):2609-2617, 2003.

114. Jagannath S, Durie BG, Wolf J, et al.: Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 129(6):776-783, 2005.

115. Harousseau JL, Attal M, Leleu X, et al.: Bortezomib plus dexamethasone as induction treatment prior to autolo-gous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 91(11):1498-1505, 2006.

116. Oakervee HE, Popat R, Curry N, et al.: PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 129(6):755-762,

Was this article helpful?

0 0
10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment